Seraphina Therapeutics has achieved a notable ranking on the 2025 Inc. 5000 list, placing as the fifth fastest-growing private consumer-products company in the United States, according to the company. It ranks 117th overall among all private firms on the list, placing it within the top 2 percent. The growth is attributed to its fatty15 supplement, the company said that.
The company claims that fatty15—a supplement based on the fatty acid C15:0—was derived from a discovery involving older Navy dolphins and has since been backed by more than 100 peer-reviewed studies, 60+ patents, and funding support from the Office of Naval Research.
According to the company, clinical studies have shown that increased intake of C15:0 through fatty15 may improve liver and red blood cell function, lower LDL cholesterol, support gut microbiome balance, reduce anxiety, and enhance vascular function within 12 weeks. It also said that 70 percent of customers—drawn from over 3,900 surveyed—reported benefits within 16 weeks.
Since its direct-to-consumer launch in January 2021, the company reported a 95 percent monthly customer retention rate and more than 100,000 active subscribers. Expansion into Amazon and healthcare provider distribution channels has helped drive what the company claims is a 3,031 percent revenue growth from 2021 to 2024.
